Aurobindo Pharma Q4 Review - Higher R&D Spend Offsets Benefit Of Better Operating Leverage: Motilal Oswal
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Aurobindo Pharma Ltd. delivered an operationally in-line Q4 FY21.
The outlook for the injectables segment continues to improve on the back of better traction in existing products, new introductions, and healthy pipeline build-up comprising complex products.
The vaccine space remains interesting for the company in terms of regulatory filings as well as contract manufacturing.
We have reduced our FY22E/FY23E earnings per share estimate by 3%/2% to reflect Covid-19 related slowdown in Europe/growth markets and increased research and development spends towards complex products.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.